BCR-ABL tyrosine kinase inhibitors (TKIs) revolutionized the treatment of chronic myeloid leukemia, inducing deep molecular responses, largely improving patient survival and rendering treatment-free remission possible. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.